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Abstract 
A common mammalian defence mechanism employed to prevent systemic dissemination of invasive 
bacteria involves occlusion of local microvasculature and encapsulation of bacteria within fibrin 
networks. Acquisition of plasmin activity at the bacterial cell surface circumvents this defence 
mechanism allowing invasive disease initiation. To facilitate this process, S. pyogenes secrete 
streptokinase, a plasminogen activating protein. Streptokinase polymorphism exhibited by S. pyogenes 
isolates is well characterised. However, the functional differences displayed by these variants and the 
biological significance of this variation has not been elucidated. Phylogenetic analysis of ska sequences 
from 28 S. pyogenes isolates revealed two main sequence clusters (clusters 1 and 2). All strains secreted 
streptokinase as determined by western blotting and were capable of acquiring cell-surface plasmin 
activity after incubation in human plasma. Whereas culture supernatants from strains containing cluster 1 
ska alleles also displayed soluble plasminogen activation activity, supernatants from strains containing 
cluster 2 ska alleles did not. Furthermore, plasminogen activation activity in culture supernatants from 
strains containing cluster 2 ska alleles could only be detected when plasminogen was pre-bound with 
fibrinogen. This study indicates that variant streptokinase proteins secreted by S. pyogenes isolates 
display differing plasminogen activation characteristics and may therefore play distinct roles in disease 
pathogenesis. 
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A common mammalian defence mechanism employed to prevent systemic dissemination of 
invasive bacteria involves occlusion of local microvasculature and encapsulation of bacteria 
within fibrin networks. Acquisition of plasmin activity at the bacterial cell surface 
circumvents this defence mechanism allowing invasive disease initiation. To facilitate this 
process, S. pyogenes secrete streptokinase, a plasminogen activating protein. Streptokinase 
polymorphism exhibited by S. pyogenes isolates is well characterised. However, the 
functional differences displayed by these variants and the biological significance of this 
variation has not been elucidated. Phylogenetic analysis of ska sequences from 28 S. pyogenes 
isolates revealed two main sequence clusters (clusters 1 and 2). All strains secreted 
streptokinase as determined by western blotting and were capable of acquiring cell-surface 
plasmin activity after incubation in human plasma. Whereas culture supernatants from strains 
containing cluster 1 ska alleles also displayed soluble plasminogen activation activity, 
supernatants from strains containing cluster 2 ska alleles did not. Furthermore, plasminogen 
activation activity in culture supernatants from strains containing cluster 2 ska alleles could 
only be detected when plasminogen was pre-bound with fibrinogen. This study indicates that 
variant streptokinase proteins secreted by S. pyogenes isolates display differing plasminogen 








Group A streptococcus (Streptococcus pyogenes; GAS) is a common bacterial pathogen 
whose virulence has been honed through the process of evolution with its singular human 
host. GAS employ numerous pathogenic mechanisms that interact specifically with human 
proteins which enable evasion of host defences and promote bacterial colonisation, 
proliferation and dissemination. As an early mammalian defence mechanism, invading 
bacterial pathogens such as GAS are confined at sites of infection through the deposition of 
fibrin networks, thereby allowing a directed inflammatory immune response to specifically 
target this area (1). To circumvent this defence mechanism, GAS subvert components of the 
host fibrinolytic system to degrade fibrin and thus spread to other areas of the body (2). 
 
A key component of the fibrinolytic system is plasminogen. Plasminogen is a 92 kDa 
glycoprotein found in plasma and extracellular fluids (3). Cleavage of the plasminogen 
activation bond (i.e. Arg561-Val562) by the specific host plasminogen activators, urokinase 
(uPA) and tissue plasminogen activator (tPA), results in the formation of the serine protease, 
plasmin (4). Plasmin has a broad substrate spectrum that includes fibrin clots and the 
extracellular matrix (4). GAS secrete streptokinase, a human specific plasminogen activating 
protein. Unlike host plasminogen activators, streptokinase lacks any intrinsic enzymatic 
activity and activates plasminogen by forming a stable 1:1 stoichiometric complex with either 
plasminogen or plasmin (5). Both complexes display the broad-spectrum protease activity of 
plasmin but this activity is unique in that it cannot be regulated by the normal plasma 
inhibitors (i.e. α2-antiplasmin and α2-macroglobulin) and can also activate other molecules of 




Plasminogen contains several distinct structural domains, consisting of the amino-terminal 
peptide, followed by Kringle domains 1–5 (K1-5) and the carboxy-terminal serine protease 
domain. K1, K4 and K5 contain lysine-binding motifs that are responsible for binding to 
fibrinogen and to plasminogen receptors (7). The circulating, soluble form of plasminogen 
(glu-plasminogen) is maintained in a closed form through lysine-dependent interaction/s 
between the amino-terminal peptide and K5. Upon binding to mammalian or bacterial 
receptors, a conformational change is induced in glu-plasminogen producing an open, 
activation-susceptible form (6, 7). 
 
GAS capture and facilitate plasminogen activation to plasmin, conferring cell-bound 
proteolytic activity, by several pathways. Plasminogen bound directly to GAS via cell-surface 
receptors such as the plasminogen-binding group A streptococcal M-like proteins (PAM) (8-
10), glyceraldehye-3-phosphate dehydrogenase (GAPDH) (11) or streptococcal enolase 
(SEN) (12), can be activated by streptokinase:plasminogen/plasmin complexes, or by host 
activators such as tissue plasminogen activator (13). Alternatively, plasmin formed in solution 
may subsequently bind to GAS cell-surface receptors (14, 15). GAS may also acquire cell-
surface plasmin activity by binding a tri-molecular complex of plasminogen, human 
fibrinogen and streptokinase (16, 17).  
 
Streptokinase alleles from GAS are polymorphic (18). Previous studies have linked 
streptokinase polymorphism with strains associated with acute post-streptococcal 
glomerulonephritis (19, 20) and with strains that exhibit skin tissue tropism (21). However, 
the functional significance of streptokinase polymorphism has not been elucidated. With the 
majority of structural and functional studies on streptokinase having been performed using the 
therapeutic streptokinase from group C streptococcus, the phenotypic differences displayed by 
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GAS streptokinase proteins has yet to be explored. This report investigates streptokinase 
polymorphism in a number of clinical GAS isolates and demonstrates that variant 
streptokinase proteins display differing plasminogen activation capacities. 
 
Materials and Methods 
GAS isolates and culture 
The 28 GAS isolates from the Northern Territory of Australia used in this study were 
collected from patients between 1990 and 1998 and their clinical source, emm type, pam 
genotype and plasminogen binding characteristics have been described in detail (17). This 
strain set was selected, as the region suffers endemic GAS infections, and the strains 
examined were epidemiologically diverse. Pam-positive isolates were defined as those 
positive for pam by Southern hybridisation and containing pam encoding A1 and A2 repeat 
regions with greater than 50% amino acid sequence homology to that of the prototype PAM 
sequence (8). The invasive GAS isolate 5448 (M type 1), the North American emm53 
impetigo isolate ALAB49 and its isogenic streptokinase deletion mutant have been described 
previously (22-26). GAS were cultured on defibrinated horse blood agar plates (Biomerieux, 
Sydney, NSW, Australia) or in Todd Hewitt broth (BD, Sydney, NSW, Australia) 




For analysis of streptokinase expression, aliquots of overnight GAS cultures were washed 
twice by centrifugation and subsequent resuspension with an equal volumes of fresh THY 
before being used to inoculate new cultures. When GAS cultures had reached mid-log phase 
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(A600 = 0.6), supernatants were harvested by centrifugation, filtered using a 0.2 µm PVDF 
syringe filter (Millipore, Sydney, NSW, Australia) and stored at -70°C until analysis. 
 
Thawed GAS culture supernatants were then concentrated 18 fold by 10% trichloroacetic acid 
precipitation prior to SDS-PAGE and Western transfer to PVDF membrane (Millipore). For 
detection of streptokinase, the membranes were immunoblotted using rabbit immune serum 
raised against commercial group C streptokinase (Sigma-Aldrich, Sydney, NSW, Australia) 
as described previously (27). 
 
Streptokinase activity 
An indirect plasminogen activation assay was used to measure streptokinase activity in GAS 
culture supernatants using the plasmin amidolytic substrate Spectrozyme® PL (American 
Diagnostica, Stamford, CT, USA), as previously described (28). Briefly, supernatants were 
defrosted on ice and a 20 μl aliquot incubated at 37°C with 100 μl 50 mM Tris, pH 7.5, 
containing 20 μg/ml glu-plasminogen (Haematologic Technologies, Essex Junction, Vermont 
USA) for 15 min. Spectrozyme® PL (20 μl of 2.5 mM) was added and absorbance at 405 nm 
was measured every 3 min for 60 min. Absorbance was plotted against time and activity rates 
were determined from the linear portion of the curve. The amount of streptokinase activity in 
each bacterial culture supernatant was converted to units/ml using a standard curve of group C 
streptokinase (Sigma-Aldrich) serially diluted in THY medium using Softmax® Pro software. 
All reactions were performed in duplicate in the presence and absence of plasminogen to 
confirm that proteolytic activity of supernatants was attributable to plasminogen activation. 
Inter-assay variation was corrected for using an internal positive control sample (250 units/ml 
of purified group C streptokinase; Sigma-Aldrich) in each assay. In assays examining the 
effects of plasminogen binding ligands on streptokinase mediated plasminogen activation, 
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human fibrinogen (Sigma), recombinant streptococcal enolase (SEN) (29) or recombinant 
PAM (30) were mixed in 1:1 stoichiometric ratios with plasminogen and pre-incubated at 
37°C for 15 min prior to the addition of bacterial culture supernatants. 
 
Cell surface plasmin activity 
Plasmin acquisition by S. pyogenes isolates after incubation in human plasma was determined 
essentially as described previously (27). Frozen plasma was purchased from the Red Cross 
Blood Bank (Sydney, NSW, Australia), defrosted on ice and pooled. Aliquots of pooled 
plasma were depleted of plasminogen by incubation at 4°C on ice with excess lysine-
sepharose® 4B (Amersham Biosciences, Sydney, NSW, Australia) for 1–2 h with gentle 
agitation. GAS were cultured overnight, washed once in PBS, pH 7.4, and resuspended to 
A600 = 0.7. Aliquots of this suspension were pelleted by centrifugation (1500 x g for 10 min) 
and resuspended in an equal volume of 100% human plasma or plasminogen-depleted plasma 
at 37°C. GAS were incubated in plasma for 3 h at 37°C, pelleted by centrifugation and 
washed twice with 1 volume of ice-cold 0.01 M EDTA, 0.1% gelatin in PBS, pH 7.4. GAS 
were resuspended in 0.1% gelatin in PBS, pH 7.4 to A600 = 0.75. Aliquots (100 µl) of this 
suspension were incubated in triplicate in the presence and absence of 20 µl Spectrozyme® 
PL (2.5 mM) at 37°C for 60 min in a 96-well plate. The reaction was quenched with 80 µl of 
1.75 M acetic acid, the plates centrifuged and A405 of supernatants determined. 
 
Plasmin activity was determined as the difference between A405 in the presence and absence 
of substrate. Isolate NS931 was included as an internal control in every experiment. Each 
isolate was assayed in at least 3 independent experiments. Plasmin equivalents and the linear 
range of the assay (A405 = 0 – 0.6) were determined using a standard curve of purified plasmin 




Streptokinase genotype  
Chromosomal DNA was extracted from GAS strains using a commercially available system 
(DNeasy Kit, Qiagen, Melbourne, Vic, Australia). The variable region of the streptokinase 
gene was PCR-amplified using previously described primers (31), sequenced using the 
BigDye Terminator cycle sequencing kit and analysed using ABI Prism Autoassembler 
software (Applied Biosystems, Melbourne, Vic, Australia). A phylogenetic tree was 
constructed for the 423 bp nucleotide sequence encoding the variable β-domain of the 
streptokinase protein of the 29 NT isolates using MEGA (32) as previously described (21). 




Differences of enzyme activities between isolates were determined using unpaired, two tailed 
Student’s t-test with 95% confidence intervals. The effect of pre-binding ligands to 
plasminogen on streptokinase activation was analysed using a one way ANOVA and a 
Newman-Keuls multi-comparison post test. All statistical analyses were carried out using 
GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA). 
 
Results 
Phylogenetic analysis of streptokinase β-domain gene sequences 
The relatedness of streptokinase alleles from 5448, ALAB49 and 28 NT GAS isolates were 
investigated by phylogenetic analysis of nucleotide sequences encoding the highly variable β-
domain of streptokinase (Figure 1). The β-domain sequences were found to cluster into two 
major groups (clusters 1 and 2) with evidence of several smaller subclusters present. This 
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phylogeny is similar to that seen in previous studies (21). The ska alleles of all pam-negative 
isolates fell within cluster 1, with the exceptions of the two emm1 isolates NS696 and 5448 
which fell within a smaller subcluster of cluster 2 alleles termed cluster 2a. The majority of 
pam-positive isolates (12/13) possessed a cluster 2 allele that was termed cluster 2b. A 
notable exception was the pam-positive isolate NS53, which possessed a cluster 1 ska allele. 
This association between cluster 2b ska alleles and pam genotype has been previously 
observed (21). 
 
Activity and expression of streptokinase allelic variants 
Streptokinase activity was determined in supernatants collected from cultures at mid-log 
phase for the 31 GAS isolates. The results demonstrate a striking difference in soluble 
plasminogen activation capacities displayed by the different streptokinase variants produced 
by each isolate. For all strains harbouring a cluster 1 ska allele, there were high levels of 
streptokinase activity present in culture supernatants (Figure 2A). These ranged from 9 to 132 
units/ml. For strains harbouring a cluster 2 ska allele, no streptokinase activity was detected in 
the culture supernatants (Figure 2A). The pam-positive strain, NS53, which contains a cluster 
1 ska allele produced measurable streptokinase activity (33 units/ml) in culture supernatants 
(Figure 2A). 
 
We next investigated whether the lack of soluble streptokinase activity seen in culture 
supernatants from strains containing a cluster 2 ska allele was due to a lack of streptokinase 
protein in culture supernatants. Western immunoblotting experiments using anti-SpeB 
polyclonal sera demonstrated that the cysteine protease SpeB, which is known to degrade 
streptokinase (33) was not present in supernatants harvested at this phase of growth (data not 
shown). This was corroborated by Western-immunoblotting performed using anti-
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streptokinase polyclonal sera as it detected an immunoreactive band ranging from 
approximately 46 to 49 kDa in culture supernatants for all GAS isolates, including those 
harbouring a cluster 2 ska allele (Figure 2B). This corresponds to the approximate size of 
streptokinase (28). The ALAB49Δska mutant strain lacked this 46 to 49 kDa immunoreactive 
band, instead producing a 27 kDa band that is consistent with the expected size of the 
truncated streptokinase protein produced by this strain (25). These results clearly show the 
lack of soluble streptokinase activity in culture supernatants from isolates with a cluster 2 ska 
allele was not attributable to a lack of streptokinase protein being present in these samples. 
 
Acquisition of cell-surface plasmin by GAS isolates in plasma 
To determine whether the secreted streptokinase protein encoded by cluster 2 ska alleles was 
inactive, an indirect assay measuring the acquisition of cell-surface bound plasmin after 
incubation in human plasma was performed for all isolates (Figure 3). Despite the apparent 
lack of streptokinase activity in solution, isolates containing a cluster 2 ska allele acquired 
significantly higher levels of plasmin activity at the cell surface compared to the isolates 
containing a cluster 1 ska allele (Figure 3; p = 0.0018). As might be expected, the isogenic 
streptokinase-negative mutant ALAB49Δska acquired significantly less cell-surface plasmin 
activity than wild-type ALAB49 (Figure 3; p = 0.019). As secreted cluster 2 type 
streptokinase appears to contribute to cell-surface plasmin acquisition, these observations 
suggest that this type of streptokinase is active but only in the presence of cell surface 
receptors and/or human plasma. 
 
Effects of plasminogen binding receptors on plasminogen activation by streptokinase 
Fibrinogen can contribute to the acquisition of cell surface plasmin activity by binding 
streptokinase-plasminogen complexes to M-proteins located on the bacterial cell surface (16). 
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The effect of pre-binding plasminogen to fibrinogen on plasminogen activation by group A 
streptococcal streptokinase variants was thus examined (Figure 4). Fibrinogen significantly 
increased the streptokinase activity detected in GAS culture supernatants from isolates 
harbouring cluster 1 ska alleles when compared to activities detected in the absence of 
fibrinogen (Figure 4A; p<0.001). Importantly, streptokinase activity was also detected in GAS 
culture supernatants from isolates harbouring the cluster 2 ska alleles when plasminogen was 
pre-bound with fibrinogen (Figure 4A). 
 
The binding of glu-plasminogen to mammalian or bacterial receptors induces a 
conformational change that can affect the activation of this zymogen (6, 7). When 
plasminogen was pre-bound to PAM, a significant increase in streptokinase activity in GAS 
culture supernatants from isolates harbouring cluster 1 and cluster 2a ska alleles was observed 
when compared to activities detected in the absence of PAM (Figure 4B; p<0.01). However, 
this enhanced streptokinase activity is not biologically relevant as the majority of cluster 1 ska 
allele GAS strains do not express PAM. GAS culture supernatants from pam-positive isolates 
harbouring a cluster 2b ska allele did not produce detectable streptokinase activity when 
plasminogen was pre-bound to PAM (Figure 2B). When plasminogen was pre-bound to SEN, 
streptokinase activity in all GAS culture supernatants was similar to levels detected in the 
absence of SEN (Figure 4C; p>0.05). When plasminogen was pre-bound to a combination of 
fibrinogen and PAM or fibrinogen and SEN, streptokinase activity was increased to levels 
similar to those seen for fibrinogen alone suggesting that the presence of PAM or SEN does 
not confer an additional benefit (Figure 4D and E). For all reaction conditions, ALAB49Δska 
did not exhibit streptokinase activity in culture supernatants (Figure 4). These data 
demonstrate that, for cluster 2 ska alleles, the presence of fibrinogen is a prerequisite for the 





Activating plasminogen and acquiring plasmin activity to the bacterial cell surface has been 
recognised as a pathogenic mechanism for a variety of bacterial species that can cause 
invasive infections (34, 35). A long standing question in group A streptococcal research has 
been the correlation of high level cell surface plasminogen binding capacity with the absence 
of detectable streptokinase activity (2, 28). In this report, we demonstrate for the first time 
that allelic variants of streptokinase produced by different GAS isolates display unique 
plasminogen activation properties which confer on all GAS isolates the potential to harness 
plasmin activity onto the bacterial cell surface. 
 
Plasminogen receptors interact with different regions of the plasminogen protein. The GAS 
plasminogen-binding M protein, PAM, binds to plasminogen via interaction with K2 (36), 
whereas fibrinogen and the GAS plasminogen receptors SEN and GAPDH bind via lysine 
dependant interactions with K1, K4 and K5 (7). Streptokinase encoded by cluster 2b ska 
alleles failed to produce any soluble plasminogen activation activity in the absence of 
fibrinogen. Pre-binding of the plasminogen receptors PAM or SEN to plasminogen did not 
enhance plasminogen activation by cluster 2b allelic variants of streptokinase. This is 
consistent with previous studies that have noted specific isolates of S. pyogenes fail to activate 
plasminogen (28). All the GAS isolates used in this current study expressed and secreted 
streptokinase into culture supernatants indicating that the lack of plasminogen activation 
activity was not due to lack of ska expression. Streptokinase encoded by cluster 2b ska alleles 
was able to activate plasminogen when pre-bound to fibrinogen or to cells pre-incubated in 
human plasma. Cluster 2b streptokinase expression by the PAM-positive strain ALAB49, was 
required for cell-surface plasmin acquisition during incubation in human plasma as deletion of 
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the ska gene in ALAB49Δska abolished surface plasmin acquisition. Streptokinase encoded 
by cluster 2a ska alleles also readily activated plasminogen to produce plasmin activity in the 
presence of fibrinogen. Taken together, these data suggest cluster 2 streptokinase requires the 
formation of a tri-molecular complex with plasminogen and fibrinogen in order to display 
plasminogen activating capability. 
 
Streptokinase encoded by cluster 1 ska alleles readily activated soluble plasminogen to 
produce plasmin activity. The addition of fibrinogen to cluster 1 ska supernatants resulted in 
significantly higher levels of streptokinase activity (Figure 4). Similarly, activation of glu-
plasminogen by group C streptokinase can be enhanced when plasminogen is pre-bound with 
fibrinogen (37). Although SEN has been shown to bind to plasminogen (38), this interaction 
did not affect plasminogen activation mediated by any of the streptokinase variants examined 
in this study. 
 
Kalia and Bessen (21) demonstrated a strong linkage disequilibrium between skin-tropic GAS 
strains, cluster 2b ska alleles and PAM suggesting the resultant phenotype may contribute to 
increased bacterial fitness during skin infection. In this study 13 of the 14 pam-positive strains 
contained a cluster 2b ska allele. Although PAM was shown to have no effect on plasminogen 
activation by streptokinase encoded by cluster 2b allele types, we hypothesise that PAM, 
rather than playing a direct role in plasminogen activation, has evolved to bind to K2 of 
plasminogen, allowing fibrinogen to interact with K4 and K5 in a non-competitive manner. 
This allows the plasminogen-fibrinogen-streptokinase tri-molecular complex to bind to the 
surface of PAM-positive GAS isolates expressing cluster 2b ska (Figure 5A). Supporting this 
hypothesis, Svensson et al. (25) showed that an isogenic pam knockout mutant of ALAB49 
failed to acquire and activate plasminogen after incubation in human plasma. Other GAS 
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plasminogen binding proteins such as SEN cannot bind this tri-molecular complex as the 
plasminogen domains (K 4 and K5) required for interaction with SEN are involved in the 
interaction with fibrinogen. This hypothesis accounts for the co-selection of PAM and cluster 
2b ska observed by Kalia and Bessen (21). For cluster 2a GAS, the fibrinogen-binding 
capacity of M1 protein (39-41) allows attachment of the tri-molecular complex to the bacterial 
surface (Figure 5B). In contrast, cluster 1 GAS produces a streptokinase molecule that does 
not require the participation of fibrinogen to activate plasminogen. We hypothesise that 
anchoring of the cluster 1 streptokinase-plasminogen complex to the GAS cell surface can 
occur via the interaction of K4 and K5 with SEN or other plasminogen receptors, or 
alternatively via the interaction of the cluster 1 streptokinase-plasminogen complex with 
fibrinogen bound to GAS fibrinogen receptors (Figure 5C). 
 
Our results show that allelic variants of streptokinase produced by different GAS strains 
exhibit differing plasminogen activation capacities. This suggests that variation within the β 
domain of these proteins may be responsible for the observed differences in plasminogen 
activation activities. Lizano and Johnston (42) have suggested that sequence polymorphism in 
the β-domain has little affect on plasminogen activation. The recombinant streptokinase 
produced from SF13013 (containing a cluster 2a ska allele) in that study displayed soluble 
plasminogen activation activity. In our study, streptokinase produced by two serotype M1 
isolates containing cluster 2a alleles displayed no soluble plasminogen activation activity. 
This indicates that sequence differences outside the β-domain region may also contribute to 





In this study, we demonstrate that activation of plasminogen by cluster 2 type streptokinase 
requires the presence of fibrinogen and the formation of a tri-molecular complex between 
streptokinase, plasminogen and fibrinogen. This requirement underpins the previously 
observed linkage disequilibrium between PAM and cluster 2b alleles (21) as PAM is critical 
for harnessing plasmin activity to the bacterial cell surface via binding of the tri-molecular 
complex. The sequence diversity of streptokinase displayed by GAS may be the result of 
selection pressures acting on ska during the infection process, thereby producing streptokinase 
proteins that are better adapted to interact with the human fibrinolytic system while avoiding a 
functional immune system. Therefore, understanding the molecular basis for the phenotypic 
variations observed in this study could assist the rational design of second generation 
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Figure 1. Phylogenetic tree for a 423 bp variable region encoding the β-domain of 
streptokinase for the 31 isolates examined in this study. The DNA sequence of the ska allele 
from ALAB49 (AY234134) was obtained from a previous study (21). Bootstrap values of ≥ 
90% (500 replicates) are indicated and the scale bar indicates 0.05 substitution per site. PAM-
positive GAS isolates are in italics. The Genbank accession numbers for the 29 partial ska 
sequences are EU352612 to EU352641. 
 
Figure 2. Solution phase streptokinase activity and expression of 31 clinical isolates of GAS. 
(A) Streptokinase activity in GAS culture supernatants at mid-log phase (A600 = 0.6) 
measured by an indirect assay of plasmin activity in the presence of human plasminogen 
using the plasmin-specific chromogenic substrate Spectrozyme® PL. Results are presented as 
the mean of streptokinase activity from duplicate assays, expressed as units/ml using a 
standard curve of group C streptokinase and corrected for an internal positive control sample 
in each assay. Error bars represent the range for each point. (B) Western blot of mid-log phase 
GAS culture supernatants using rabbit immune serum raised against group C streptokinase. 
GAS isolates containing a cluster 1 ska allele are indicated with a solid horizontal bar while 
isolates containing a cluster 2 ska allele are indicated with a dashed horizontal bar. GAS 
isolates containing a sub-cluster 2a ska allele are underlined. PAM-positive GAS isolates are 
in italics. 
 
Figure 3. Cell-surface plasmin activity of GAS isolates. Cell surface plasmin activity of 32 
clinical isolates of GAS following incubation in human plasma (filled bars) or plasminogen-
depleted plasma (unfilled bars) determined by cleavage of Spectrozyme® PL. Data represent 
mean ± SEM of triplicate cultures of GAS, expressed as A405 of cleaved substrate in solution. 
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Overall, strains containing cluster 2 ska alleles acquire more cell-surface plasmin activity 
compared to Strains containing cluster 1 ska alleles (p = 0.0018). GAS isolates containing a 
cluster 1 ska allele are indicated with a solid horizontal bar while isolates containing a cluster 
2 ska allele are indicated with a dashed horizontal bar. GAS isolates containing a sub-cluster 
2a ska allele are underlined. PAM-positive GAS isolates are in italics. 
 
Figure 4. Streptokinase activity in GAS culture supernatants at mid-log phase (A600 = 0.6) 
measured by an indirect assay of plasmin activity in the presence of human plasminogen pre-
bound with fibrinogen (A), PAM (B), SEN (C), fibrinogen and PAM (D) or fibrinogen and 
SEN (E). Results are presented as the mean of streptokinase activity from duplicate assays, 
expressed as units/ml using a standard curve of group C streptokinase and corrected for an 
internal positive control sample in each assay. Error bars represent the range for each point. 
GAS isolates containing a cluster 1 ska allele are indicated with a solid horizontal bar while 
isolates containing a cluster 2 ska allele are indicated with a dashed horizontal bar. GAS 
isolates containing a sub-cluster 2a ska allele are underlined. PAM-positive GAS isolates are 
in italics. 
 
Figure 5. Schematic diagram summarising the hypothesised pathways of cell surface plasmin 
acquisition by GAS strains expressing different alleles of streptokinase. (A) Cluster 2b 
streptokinase must combine with plasminogen and fibrinogen to form a tri-molecular complex 
that exhibits plasmin activity. The tri-molecular complex is bound to the cell surface via the 
interaction between PAM and kringle 2 of plasminogen. Other GAS plasminogen binding 
proteins such as SEN cannot bind this tri-molecular complex as the domains K 4 and K5 
required for interaction are involved in the interaction with fibrinogen. (B) Cluster 2a 
streptokinase also must combine with plasminogen and fibrinogen to form a tri-molecular 
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complex that exhibits plasmin activity. The tri-molecular complex is bound to the cell surface 
via the interaction between fibrinogen binding receptors (FgR) such as M1 protein and 
fibrinogen. (C) Cluster 1 type streptokinase will combine with plasminogen to form a 
complex with plasmin activity. This complex can be bound directly to the bacterial cell 
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